On May 13, 2015, Danaher Corp. (NYSE: DHR) announced its intention to separate its science & technology and diversified industrials businesses into two independent, publicly traded companies via a tax-free spin-off to shareholders. The transaction is expected to be completed around the end of calendar year 2016, subject to final Board approval, satisfactory completion of financing, and receipt of other regulatory approvals. Danaher is a global medical and industrial conglomerate consisting of technology, medical, science, and industrial products with a market capitalization exceeding $50 billion and revenue of $19.1 billion and $19.9 billion in F2013 and F2014 respectively (4% revenue growth). The company’s revenue mix consists of Test & Measurement (17% of 2014 revenue); Environmental (18%), which primarily consists of water quality instrumentation systems; Life Sciences & Diagnostics (36%), which consists of analytical instruments used by hospitals and laboratories; Dental (11%), and Industrial Technologies (18%).
The parent, a science and technology growth company, which will retain the Danaher name, generated approximately $16.5 billion in revenues in 2014, including Pall Corporation (NYSE: PLL), which the company separately today announced an agreement to acquire. Post-spin Danaher will consist of the company’s Environmental, Life Sciences & Diagnostics, and Dental segments and is expected to generate gross margin in excess of 50% and operating margin in the mid-teens, while 60% of sales are into the aftermarket channel.
SpinCo is a diversified industrial growth company, consisting primarily of Danaher’s industrial automation and test & measurement businesses, generating approximately $6.0 billion in revenues in the most recently completed fiscal year. The business is expected to generate gross margin of approximately 50%, operating margin in the high teens, and significant free cash flow generation.
Notably, in October 2014 Danaher announced plans to split off its communications test business, which is to be acquired by Netscout Systems (NASDAQ: NTCT) in a Reverse Morris Trust (RMT) transaction. This transaction is expected to be completed in the June to September timeframe. This business generated $835 million in C2014 revenues. For more details on this transaction, please refer to The Spin-Off Report dated March 26, 2015. Danaher shareholders will own approximately 60% of the merged Netscout entity.
Danaher has a 30-year-plus track record of deploying its considerable free cash flow (over $3 billion annually) in high-return acquisitions. More recently, management has been very vocal about its interest in larger deals, although speculation has largely centered on diagnostics companies such as Waters Corp. (NYSE: WAT), PerkinElmer Inc. (NYSE: PKI), and Agilent Technologies (NYSE: A) as potential targets. The acquisition of Pall, which was only yesterday reported to be in auction, strategically complements Danaher’s existing water filtration and purification business within its Environmental business segment. Danaher is to acquire all outstanding shares of Pall for $127.20 per share in cash, or a total enterprise value of approximately $13.8 billion (including assumed debt and net of acquired cash), or a multiple of 4.9x 2014 sales. Pall is a leading provider of filtration, separation and purification solutions that remove contaminants or separate substances from a variety of solids, liquids, and gases. The company generated revenues of $2.8 billion for its fiscal year ended July 2014, consisting of $1.5 billion from its Life Sciences segment and $1.3 billion from its Industrial segment. The acquisition is expected to be approximately $0.40 accretive to non-GAAP adjusted diluted net earnings per share in 2016. The filtration/separation market remains highly attractive, growing in the mid to high single digits annually with gross margins of 50%. The valuation, at approximately 20x estimated 2015 EBITDA of $682 million is similar to last year’s acquisition of Sigma –Aldrich by Merck (NYSE: MRK). Pall represents Danaher’s largest acquisition since acquiring Beckman Coulter in 2011. Danaher’s rival bidder was reported to be Thermo Fisher Scientific (NYSE: TMO).
The post-spin parent company can be compared with Medical, Life Sciences and Diagnostics, and Dental manufacturers including Dentsply International Inc. (NASDAQ: XRAY), Sirona Dental Systems Inc. (NASDAQ: SIRO), and Varian Medical Systems (NYSE: VAR), as well as water test and purification manufacturers such as Esco Technologies (NYSE: ESE). On an enterprise value to trailing sales basis, these companies trade at a multiple of 3.1x. Applying this multiple to C2014 revenues of $16,500 million generates an implied enterprise value of $51,150 million for post-spin Danaher.
The SpinCo can be compared with diversified industrial testing companies such as Anritsu (6754 JP), Cobham plc (COB LN), and National Instruments Corp. (NASDAQ: NATI). On an enterprise value to trailing sales basis, these companies trade at 2.8x. Applying this multiple to $5,165 million in C2014 revenues generates an implied enterprise value of $14,462 million for the SpinCo. The SpinCo revenue estimate nets out $835 million in sales that will be split off in the NTCT transaction. DHR shareholders will own 60% of NTCT following the split off, valued at $1 billion based on Netscout’s current market capitalization.
A pre-spin fair value estimate of $93 per share is derived from this preliminary exercise when accounting for $736 million in net debt and 708 million shares outstanding. This sum-of-the-parts fair value estimate represents 6.6% upside to the shares’ current price of $87.38.